ImmunityBio (NASDAQ: IBRX) is rapidly transforming into a commercial powerhouse, fueled by the explosive growth of its lead immunotherapy, ANKTIVA. Following a year of breakthrough regulatory wins and clinical milestones, the company has reported a staggering 700% year-over-year increase in preliminary net product revenue, reaching approximately $113 million for 2025.

Commercial Momentum and Global Reach

The company’s financial trajectory has caught the attention of Wall Street, with Piper Sandler recently raising its price target to $7.00. Analysts now project 2026 revenues could climb as high as $256 million as the drug penetrates deeper into the bladder cancer market.

Beyond the U.S., ANKTIVA is gaining significant international traction:

Middle East Expansion: The Saudi Food and Drug Authority recently granted accelerated approval for ANKTIVA in both non-muscle invasive bladder cancer (NMIBC) and metastatic non-small cell lung cancer (NSCLC).

European Footprint: Along with existing approvals in the United Kingdom, the drug has received a positive opinion for conditional marketing authorization in the European Union.

Clinical Frontiers: Advancing “Chemo-Free” Treatments

ImmunityBio continues to advance its clinical pipeline. On February 2, 2026, the company initiated ResQ215B, a Phase 2 study for a chemotherapy-free combination in indolent B-cell non-Hodgkin lymphoma. Updated Phase 2 results from the glioblastoma (GBM) program also show promise, with median overall survival not yet reached in a challenging patient group. Dr. Patrick Soon-Shiong, Founder and Executive Chairman, highlighted the potential of the BioShield platform as “Immunotherapy 2.0,” aiming for anti-tumor activity without traditional treatment toxicities.

Investor Outlook

Despite ongoing net losses and a new securities investigation by Pomerantz Law Firm following a stock dip in January, major brokerages maintain a positive outlook. Brokerage ratings and price targets include D. Boral Capital (Buy, $24.00), HC Wainwright (Buy, $10.00), BTIG Research (Buy, $9.00), Jefferies (Buy, $9.00), and Piper Sandler (Overweight, $7.00). More details on commercial progress and pipeline updates are available via the ImmunityBio Investor Relations portal.

Another biotech stock that needs attention is NanoViricides, Inc. (NYSE: NNVC), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, recently today that President Dr. Anil R. Diwan was interviewed on the Mission Matters Podcast by Mr. Adam Torres. The interview video is available at https://youtu.be/nU_2dgd-u1g.

Dr. Diwan explained that NV-387 had shown excellent effectiveness in lethal animal models of infections of viruses including Influenza, RSV, Coronaviruses, MPox, Smallpox as well as Measles. In fact NV-387 treatment led to complete cure of RSV infection in lethally infected animals. Additionally, NV-387 was found to be substantially superior to existing influenza therapeutics, namely Tamiflu (oselatmivir) and Xofluza (baloxavir) in a lethal infection animal model. There is no approved therapy for MPox. Two drugs approved under the US FDA “Animal Rule” process, namely tecovirimat and brincidofovir were put into clinical trials for treatment of MPox. Tecovirimat failed to show improvement over the standard of care. Brincidofovir was dosed in an initial cohort in January, 2025 but no data can be found about its effects, and the clinical trial does not appear to have advanced further. Previously, in three MPox cases treated in the UK under emergency use protocols, brincidofovir led to significant elevation of liver enzymes and the drug was discontinued. No efficacy signal was found in these three cases.

There is no approved therapy for treatment of RSV infection, other than the toxic ribavirin as a last resort. Three antibodies have been approved for treatment of newborns so that they would not come down with RSV infection. A vaccine has been approved for treatment of expectant mothers despite risk of early/preterm births. These approvals indicate the severity of the problem and the need for an actual treatment of RSV infection.

Dr. Diwan advised that NV-387 has completed Phase I clinical trial in healthy subjects with no reported adverse events. He further stated that a Phase II clinical trial to test NV-387 for efficacy against Mpox (Monkeypox) virus is ready to begin soon. The ACOREP regulatory agency of the Democratic Republic of Congo (DRC) has already given permission for the clinical trial. The clinical trial application process has been completed. The trial is expected to begin with dosing of the first cohort of patients once the clinical site preparations are completed. NV-387 is estimated to address a market potential of over $17 Billion by 2030 if approved, based on its broad spectrum and multiple indications. Trading at less than a dollar with a 52-week high of over $2.00, NNVC has significant upside potential. As always, conduct your own due diligence and exercise trader vigilance

Source:

https://ir.immunitybio.com/node/11061/pdf

https://finance.yahoo.com/news/nanoviricides-president-dr-diwan-interviewed-133000134.html

Disclaimer: This blog post is for informational purposes only and does not constitute financial advice or an endorsement of NNVC or its strategies. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Please ensure to fully read and comprehend our disclaimer found at https://UsaStockReport.com/disclaimer/. https://UsaStockReport.com/ expects to be compensated five thousand dollars for content distribution services on NNVC by Interactive Offers LLC .https://UsaStockReport.com/ is neither an investment advisor nor a registered broker. No current owner, employee, or independent contractor of https://UsaStockReport.com/ is registered as a securities broker-dealer, broker, investment advisor, or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. This article may contain forward-looking statements as defined under Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. These statements, often incorporating terms like “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or similar expressions about future performance or conduct, are based on present expectations, estimates, and projections, and are not historical facts. They carry various risks and uncertainties that may result in significant deviation from the anticipated results or events. Past performance does not guarantee future results.https://UsaStockReport.com/ does not commit to updating forward-looking statements based on new information or future events. Readers are encouraged to review all public SEC filings made by the profiled companies at https://www.sec.gov/edgar/searchedgar/companysearch. It is always important to conduct thorough due diligence and exercise caution in trading. https://UsaStockReport.com/ is not managed by a licensed broker, a dealer, or a registered investment adviser. The content here is purely informational and should not be taken as investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor regarding forward-looking statements. Any statement that projects, foresees, expects, anticipates, estimates, believes, or understands certain actions to possibly occur are not historical facts and may be forward-looking statements. These statements are based on expectations, estimates, and projections that could cause actual results to differ greatly from those anticipated. Investing in micro-cap and growth securities is speculative and entails a high degree of risk, potentially leading to a total or substantial loss of investment. Please note that no content published here constitutes a recommendation to buy or sell a security. It is solely informational, and you should not construe it as legal, tax, investment, financial, or other advice. No content in this article constitutes an offer or solicitation by https://UsaStockReport.com/ or any third-party service provider to buy or sell securities or other financial instruments. The content in this article does not address the circumstances of any specific individual or entity and does not constitute professional and/or financial advice. https://UsaStockReport.com/ is not a fiduciary by virtue of any person’s use of or access to this content. This article is for informational purposes only and does not constitute investment advice. Always conduct your own research before making investment decisions.

Media Contact
Company Name: UsaStockReport
Contact Person: Ash K
Email: editor@usastockreport.com
City: Frisco
State: Texas
Country: United States
Website: https://usastockreport.com/